Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
225Ac-FL-020
i
Other names:
225Ac-FL-020, [225Ac]Ac-FL-020
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Full-Life Technologies Limited
Drug class:
Alpha radiation emitter, PSMA inhibitor
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
Iomab-ACT (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
lutetium Lu 177 vipivotide tetraxetan (4)
PNT2002 (2)
INO-5401 (1)
JNJ-63898081 (1)
177Lu-LNC1003 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
AB-2100 (0)
ALF501 (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
Iomab-ACT (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
lutetium Lu 177 vipivotide tetraxetan (4)
PNT2002 (2)
INO-5401 (1)
JNJ-63898081 (1)
177Lu-LNC1003 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
AB-2100 (0)
ALF501 (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
9ms
Study With [225Ac]Ac-FL-020 in mCRPC Participants (clinicaltrials.gov)
P1, N=35, Recruiting, Full-Life Technologies GmbH | Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Oct 2024
9 months ago
Enrollment open • Trial initiation date
|
225Ac-FL-020
11ms
Phase 1 With [225Ac]Ac-FL-020 in mCRPC Participants (clinicaltrials.gov)
P1, N=35, Not yet recruiting, Full-Life Technologies GmbH
11 months ago
New P1 trial
|
225Ac-FL-020
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login